ReviewDiabetologia2026
Unravelling the developmental origins of cystic fibrosis-related diabetes.
Review in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cystic fibrosis (CF)-related diabetes (CFRD) is a growing and evolving concern for people living with cystic fibrosis. As its own unique clinical entity, there is an urgent need to better understand this complex health challenge to improve the quality of life for people with CF. Unfortunately, many aspects of CFRD pathophysiology and pathogenesis remain unclear, resulting in a disparity in the standard of care provided. An emerging body of evidence supports that CFRD may have developmental origins, as people with CF present with pancreatic pathology and glucose abnormalities as early as in utero. This therefore suggests that the CF transmembrane conductance regulator (CFTR) gene mutations that cause CF may impair pancreatic organogenesis, thus leading to CFRD. This review consequently aims to summarise the existing evidence that may support a fundamentally vital role of CFTR in the development of the pancreas. From aspects of the endocrine and exocrine pancreas to scrutinising the broader islet microenvironment, the many constituents at play in pancreatic organogenesis are highlighted. Unravelling the deeper complexities of CFRD pathogenesis will not only clarify existing knowledge gaps but may transform the way future care is provided.
Indexed as
Identifiers
42262528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.